M&A Deal Summary

Pfizer Acquires Array BioPharma

On June 17, 2019, Pfizer acquired life science company Array BioPharma for 11.4B USD

Acquisition Highlights
  • This is Pfizer’s 30th transaction in the Life Science sector.
  • This is Pfizer’s 8th largest (disclosed) transaction.
  • This is Pfizer’s 25th transaction in the United States.
  • This is Pfizer’s 1st transaction in Colorado.

M&A Deal Summary
Date 2019-06-17
Target Array BioPharma
Sector Life Science
Buyer(s) Pfizer
Deal Type Add-on Acquisition
Deal Value 11.4B USD
Advisor(s) Centerview Partners (Financial)
Skadden, Arps, Slate, Meagher & Flom (Legal)

Target

Array BioPharma

Boulder, Colorado, United States
Array BioPharma, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six Phase 3 studies on Array invented drugs, binimetinib (partnered with Novartis) and selumetinib (partnered with AstraZeneca), are currently enrolling patients with cancer. Array BioPharma, Inc. was formed in 1998 and is headquartered in Boulder, Colorado.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States
Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.

DEAL STATS #
Overall 34 of 44
Sector (Life Science) 30 of 39
Type (Add-on Acquisition) 24 of 31
State (Colorado) 1 of 1
Country (United States) 25 of 32
Year (2019) 3 of 3
Size (of disclosed) 8 of 22
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-05-08 Therachon AG

Basel, Switzerland

Therachon AG is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with significant unmet need. Therachon AG was founded in 2014 and is based in Basel, Switzerland.

Buy $810M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-29 The Upjohn Company

Kalamazoo, Michigan, United States

Upjohn seeks to leverage our portfolio, global experience and expertise to become the trusted partner of choice for all stakeholders committed to improving patient health. Upjohn focuses on relieving the burden of non-communicable diseases with trusted, quality medicines for every patient, everywhere. Upjohn brings together 20 of the industry's most trusted brands — products such as Lipitor, Norvasc, Lyrica and Viagra — with world-class medical, manufacturing and commercial expertise in more than 120 countries.

Sell -
Mergr

Product

Company

Legal